Table 2.
CYP2C9 and CYP2C19 allelic and PM genotypic frequencies in the DILI group compared with other populations studied
| Population study | Number of subjects | *1 | *2 | *3 | PM | Reference |
|---|---|---|---|---|---|---|
| CYP2C9 | ||||||
| DILI group | 28 | 71 | 13 | 16 | 4 | Our study |
| Caucasian | 157 | 69 | 14 | 16 | 7 | Garcia-Martin et al. (2001) |
| Asian | 102 | 95 | 0 | 5 | 0 | Gaedigk et al. (2001) |
| North American | 325 | 78 | 15 | 7 | 4 | Gaedigk et al. (2001) |
| CYP2C19 | ||||||
| DILI group | 32 | 86 | 14 | 0 | 3 | Our study |
| Caucasian | 360 | 89 | 11 | 0 | 2 | Scordo et al. (2004) |
| Asian | 121 | 50 | 45.5 | 4.5 | 24 | Yamada et al. (2001) |
| African American | 108 | 75 | 25 | 0 | 7 | Goldstein et al. (1997) |
Abbreviations: DILI, drug-induced liver injury; PM, poor metabolizer.